Publications by authors named "G Peter Frick"

Claim this Profile
L
Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension.
Tuan H Vu, Renato Mantegazza, Djillali Annane, Masahisa Katsuno, Andreas Meisel, Glen Frick

Eur J Neurol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can patient self-evaluation of functional status be used for evaluation of impairment of motor function in Guillain-Barré syndrome? Mapping clinician- and patient-reported outcomes in a phase 3 study of eculizumab in Japan.
Antoine Regnault, Angély Loubert, Stéphane Quéré, Qun Lin, Glen Frick

Front Neurol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of eculizumab in Guillain-Barré syndrome: A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial.
Satoshi Kuwabara, Susumu Kusunoki, Motoi Kuwahara, Yoshihisa Yamano, Yoichiro Nishida, Glen Frick

J Peripher Nerv Syst· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study.
John F Brandsema, Matthew Ginsberg, Hideki Hoshino, Masakazu Mimaki, Satoru Nagata, Glen Frick

Pediatr Neurol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.
Angela Genge, Leonard H van den Berg, Glen Frick, Steve Han, Cori Abikoff

JAMA Neurol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis